Osimertinib with or without Chemotherapy in EGFR-Mutated Advanced NSCLC.

已完结 10 由 wocause 发布于 2026/5/10 18:30:57

DOI:10.1056/NEJMoa2306434
作者：David Planchard,?Pasi A J?nne,?Ying Cheng,?James C-H Yang,?Noriko Yanagitani,?Sang-We Kim,?Shunichi Sugawara,?Yan Yu,?Yun Fan,?Sarayut L Geater,?Konstantin Laktionov,?Chee K Lee,?Natalia Valdiviezo,?S
文献类型：期刊论文
补充材料：只需要正文

New England Journal of Medicine (NEJM)

Abstract：Background: Osimertinib is a third-generation epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) that is selective for EGFR-TKI-sensitizing and EGFR T790M resistance mutat

应助信息

求助已完结，文件已删除 如有需求请重新发布求助一键发布

感谢使用Book学术
本站所有文献仅供个人学习和参考，请勿将文件进行传播。共同遵守网站规定和相关知识产权规定。

上一个求助:其它数据库Naturally Fractured Carbonate Reservoir Characterization: A Case Study of a Mature High-Pour Point Oil Field in Hungary 下一个求助:ElsevierCa-cluster-constructed deep-ultraviolet nonlinear-optical crystal Na2Ca17Al2(PO4)14 with strong NLO response